The Food and Drug Administration approved Oculus Innovative Sciences Inc.'s (Nasdaq: OCLS) skin and wound gel Microcyn as a prescription treatment as well as an over the counter treatment. The stock price jumped $2.90 to close at $4.10.
FDA Approves Oculus' Microcyn
May 27, 2009 at 17:33 PM EDT
